GSK's Avandia woes continue, study finds a new way to identify adverse events, and Royalty ups its bid for Elan.
The FDA's opioid REMS safety plan is challenged on two fronts: getting CME providers to offer courses and getting doctors to attend them. Can the agency's scheme educate enough physicians to curb an epidemic?
A potentially dangerous and oft-abused class of painkillers will be required to have REMS risk management programs in place under an FDA edict covering all extended release and long-acting opioid analgesics, a category covering 30 drugs manufactured by 20 companies.
The general consensus surrounding the FDA advisory panel's 8-2 vote in favor of Pfizer's rheumatoid arthritis hopeful tofacitinib yesterday was that Abbott's Humira doesn't have to watch its back.
The FDA approved Bristol-Myers Squibb's cancer biologic Yervoy (ipilimumab) for the treatment of late-stage melanoma, a particularly deadly form of skin cancer for which treatment options are few. One analyst projected that sales of the drug could top $1.7 billion by 2015.
Covidien launched a patient safety organization - the Collaborating & Acting Responsibly to Ensure Safety (CARES) Alliance - today, featuring tools and resources for patients, physicians and pharmacists.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.